Stoke Therapeutics (STOK) Competitors

Stoke Therapeutics (NASDAQ:STOK) and Kymera Therapeutics (NASDAQ:KYMR) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, media sentiment, institutional ownership, earnings, risk, analyst recommendations, valuation and dividends.

Which has stronger earnings & valuation, STOK or KYMR?

Stoke Therapeutics has higher earnings, but lower revenue than Kymera Therapeutics. Kymera Therapeutics is trading at a lower price-to-earnings ratio than Stoke Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Stoke Therapeutics	$36.56M	27.30	-$88.98M	$0.79	23.05
Kymera Therapeutics	$47.07M	64.76	-$223.86M	-$3.47	-12.29

Is STOK or KYMR more profitable?

Stoke Therapeutics has a net margin of 26.25% compared to Kymera Therapeutics' net margin of -616.03%. Stoke Therapeutics' return on equity of 18.32% beat Kymera Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Stoke Therapeutics	26.25%	18.32%	15.48%
Kymera Therapeutics	-616.03%	-31.60%	-27.12%

Which has more risk and volatility, STOK or KYMR?

Stoke Therapeutics has a beta of 1.15, meaning that its stock price is 15% more volatile than the S&P 500. Comparatively, Kymera Therapeutics has a beta of 2.18, meaning that its stock price is 118% more volatile than the S&P 500.

Do analysts prefer STOK or KYMR?

Stoke Therapeutics currently has a consensus target price of $25.17, indicating a potential upside of 38.20%. Kymera Therapeutics has a consensus target price of $59.11, indicating a potential upside of 38.66%. Given Kymera Therapeutics' higher probable upside, analysts clearly believe Kymera Therapeutics is more favorable than Stoke Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Stoke Therapeutics	0 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	3.25
Kymera Therapeutics	0 Sell rating(s)	1 Hold rating(s)	16 Buy rating(s)	3 Strong Buy rating(s)	3.10

Does the media refer more to STOK or KYMR?

In the previous week, Stoke Therapeutics had 2 more articles in the media than Kymera Therapeutics. MarketBeat recorded 27 mentions for Stoke Therapeutics and 25 mentions for Kymera Therapeutics. Stoke Therapeutics' average media sentiment score of 0.63 beat Kymera Therapeutics' score of 0.44 indicating that Stoke Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Stoke Therapeutics	3 Very Positive mention(s)	5 Positive mention(s)	9 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Kymera Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	7 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Neutral

Summary

Stoke Therapeutics beats Kymera Therapeutics on 9 of the 15 factors compared between the two stocks.